OKYO

OKYO Pharma Ltd

Add to Watchlist

Advanced Chart

2.450

-0.18(-6.844%)1D

Line

Candle

YTD

High

2.610

Open

2.550

VWAP

2.47

Vol

125.37K

Mkt Cap

92.15M

Low

2.3327

Amount

309.65K

EV/EBITDA(TTM)

Total Shares

33.24M

90.13M

EV/OCF(TTM)

P/S(TTM)

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

2 Analyst Rating

Wall Street analysts forecast OKYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKYO is 10.00 USD with a low forecast of 7.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.450

Low

7.00

Averages

10.00

High

13.00

Current: 2.450

Low

7.00

Averages

10.00

High

13.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-02-18

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-02-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-02-14

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-02-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-02-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-02-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for OKYO Pharma Ltd (OKYO.O) is -13.24, compared to its 5-year average forward P/E of -5.43. For a more detailed relative valuation and DCF analysis to assess OKYO Pharma Ltd 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.43

Current PE

-13.24

Overvalued PE

-1.48

Undervalued PE

-9.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.19

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.81

Undervalued EV/EBITDA

-5.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.04

Current PS

2.45

Overvalued PS

0.35

Undervalued PS

-0.28